Targeting CSCs in tumor microenvironment: The potential role of ROS-associated miRNAs in tumor aggressiveness

Current Stem Cell Research and Therapy

Volumn 9, Issue 1, 2014, Pages 22-35

  Bao, Bin ^a   Azmi, Asfar S ^a   Li, Yiwei ^a   Ahmad, Aamir ^a   Ali, Shadan ^a   Banerjee, Sanjeev ^a   Kong, Dejuan ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CSCs; EMT; Genistein; Hypoxia; miRNAs; ROS

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENESIS; CELL HYPOXIA; EPITHELIAL-MESENCHYMAL TRANSITION; GENISTEIN; HUMANS; MICRORNAS; NEOPLASMS; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TUMOR MICROENVIRONMENT;

EID: 84903245619     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X113089990053     Document Type: Article

References (209)

1. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010; 38(1): 96-109.
2. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res 2004; 37(8): 1263-73.
3. Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J Biol Chem 1997; 272(30): 18515-7.
4. Han D, Antunes F, Canali R, et al. Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem 2003; 278(8): 5557-63.
5. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30(11): 1191-212.
6. Castro L, Alvarez MN, Radi R. Modulatory role of nitric oxide on superoxide-dependent luminol chemiluminescence. Arch Biochem Biophys 1996; 333(1): 179-88.
7. Castro L, Freeman BA. Reactive oxygen species in human health and disease. Nutrition 2001; 17(2): 161, 163-1, 165.
8. Lachance PA, Nakat Z, Jeong WS. Antioxidants: an integrative approach. Nutrition 2001; 17(10): 835-8.
9. Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. Coron Artery Dis 2001; 12(6): 455-61.
10. DeCoursey TE, Morgan D, Cherny VV. The voltage dependence of NADPH oxidase reveals why phagocytes need proton channels. Nature 2003; 422(6931): 531-4.
11. Forman HJ, Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002; 166(12 Pt 2): S4-S8.
12. Zalba G, San JG, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38(6): 1395-9.
13. Bettger WJ. Zinc and selenium, site-specific versus general antioxidation. Can J Physiol Pharmacol 1993; 71(9): 721-4.
14. Stadtman ER. Protein oxidation and aging. Science 1992; 257(5074): 1220-4.
15. Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007; 13(3): 789-94.
16. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001; 3(5): 323-7.
17. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006; 25(4): 695-705.
18. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3(7): 730-7.
19. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414(6859): 105-11.
20. Wang X, Tu Q, Zhao B, et al. Effects of poly(l-lysine)-modified Fe(3)O(4) nanoparticles on endogenous reactive oxygen species in cancer stem cells. Biomaterials 2013; 34(4): 1155-69.
21. Bao B, Ahmad A, Li Y, et al. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets 2012; 16(10): 1041-54.
22. Gangemi R, Paleari L, Orengo AM, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem 2009; 16(14): 1688-703.
23. Kitamura H, Okudela K, Yazawa T, et al. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009; 66(3): 275-81.
24. Li Y, Kong D, Ahmad A, et al. Pancreatic cancer stem cells: Emerging target for designing novel therapy. Cancer Lett 2013; 338(1): 94-100.
25. Yu C, Yao Z, Jiang Y, et al. Prostate cancer stem cell biology. Minerva Urol Nefrol 2012; 64(1): 19-33.
26. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15(2): 253-60.
27. Hermann PC, Bhaskar S, Cioffi M, et al. Cancer stem cells in solid tumors. Semin Cancer Biol 2010; 20(2): 77-84.
28. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008; 26(17): 2806-12.
29. Ischenko I, Seeliger H, Kleespies A, et al. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg 2010; 395(1): 1-10.
30. Bauerschmitz GJ, Ranki T, Kangasniemi L, et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 2008; 68(14): 5533-9.
31. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007; 67(8): 3560-4.
32. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68(1): 190-7.
33. Sarkar FH, Li Y, Wang Z, et al. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 2009; 64(5): 489-500.
34. Narducci MG, Scala E, Bresin A, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006; 107(3): 1108-15.
35. Klein RS, Rubin JB, Gibson HD, et al. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development 2001; 128(11): 1971-81.
36. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1(3): 313-23.
37. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120): 756-60.
38. Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 2010; 13(4-5): 109-18.
39. Wang Z, Li Y, Ahmad A, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8(1): 27-33.
40. Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004; 431(7011): 997-1002.
41. Tsatmali M, Walcott EC, Crossin KL. Newborn neurons acquire high levels of reactive oxygen species and increased mitochondrial proteins upon differentiation from progenitors. Brain Res 2005; 1040(1-2): 137-50.
42. Shi X, Zhang Y, Zheng J, et al. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 2012; 16(11): 1215-28.
43. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458(7239): 780-3.
44. Lopez J, Poitevin A, Mendoza-Martinez V, et al. Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 2012; 12: 48.
45. Wang Z, Li Y, Kong D, et al. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 2010; 11(6): 745-51.
46. Hugo H, Ackland ML, Blick T, et al. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213(2): 374-83.
47. Haase VH. Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int 2009; 76(5): 492-9.
48. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172(7): 973-81.
49. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 2011; 11(8): 714-23.
50. Graham TR, Zhau HE, Odero-Marah VA, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68(7): 2479-88.
51. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66(17): 8319-26.
52. Eger A, Stockinger A, Schaffhauser B, et al. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 2000; 148(1): 173-88.
53. Jing Y, Han Z, Zhang S, et al. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci 2011; 1: 29.
54. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010; 5(8): e12445.
55. Wu KJ, Yang MH. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection. Biosci Rep 2011; 31(6): 449-55.
56. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev 2012; 31: 285-93.
57. Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66(23): 11271-8.
58. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106(2): 243-7.
59. Li Y, Maitah MY, Ahmad A, et al. Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opin Ther Targets 2012; 16(1): 49-66.
60. Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24-phenotype. BMC Cancer 2010; 10: 411.
61. Cannito S, Novo E, di Bonzo LV, et al. Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal 2010; 12(12): 1383-430.
62. Giannoni E, Parri M, Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal 2012; 16(11): 1248-63.
63. Mori K, Shibanuma M, Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 2004; 64(20): 7464-72.
64. Dong R, Lu JG, Wang Q, et al. Stabilization of Snail by HuR in the process of hydrogen peroxide induced cell migration. Biochem Biophys Res Commun 2007; 356(1): 318-21.
65. Chang J, Jiang Z, Zhang H, et al. NADPH oxidase-dependent formation of reactive oxygen species contributes to angiotensin II-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. Int J Mol Med 2011; 28(3): 405-12.
66. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436(7047): 123-7.
67. Barnett P, Arnold RS, Mezencev R, et al. Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. Biochem Biophys Res Commun 2011; 404(1): 34-9.
68. Fraker CA, Ricordi C, Inverardi L, et al. Oxygen: a master regulator of pancreatic development? Biol Cell 2009; 101(8): 431-40.
69. Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. Dev Cell 2009; 17(6): 755-73.
70. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 2008; 9(4): 285-96.
71. Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 2005; 102(13): 4783-8.
72. Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9(5): 617-28.
73. Chen HL, Pistollato F, Hoeppner DJ, et al. Oxygen tension regulates survival and fate of mouse central nervous system precursors at multiple levels. Stem Cells 2007; 25(9): 2291-301.
74. Panchision DM. The role of oxygen in regulating neural stem cells in development and disease. J Cell Physiol 2009; 220(3): 562-8.
75. Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28(45): 3949-59.
76. McCord AM, Jamal M, Shankavaram UT, et al. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009; 7(4): 489-97.
77. Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010; 7(3): 380-90.
78. Bao B, Azmi AS, Ali S, et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 2012; 1826(2): 272-96.
79. Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102(5): 789-95.
80. Zeng W, Wan R, Zheng Y, et al. Hypoxia, stem cells and bone tumor. Cancer Lett 2011; 313(2): 129-36.
81. Li Z, Rich JN. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 2010; 345: 21-30.
82. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011; 71(13): 4640-52.
83. Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006; 20(5): 557-70.
84. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14(6): 435-46.
85. Bar EE, Lin A, Mahairaki V, et al. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010; 177(3): 1491-502.
86. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15(6): 501-13.
87. Pietras A, Gisselsson D, Ora I, et al. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol 2008; 214(4): 482-8.
88. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011; 17(15): 4936-41.
89. Wang Y, Liu Y, Malek SN, et al. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8(4): 399-411.
90. Heddleston JM, Li Z, McLendon RE, et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8(20): 3274-84.
91. Skuli N, Liu L, Runge A, et al. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009; 114(2): 469-77.
92. Wang Z, Li Y, Sarkar FH. Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression. Curr Stem Cell Res Ther 2010; 5(1): 74-80.
93. Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008; 29(12): 2267-78.
94. Gorlach A, Kietzmann T. Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors. Methods Enzymol 2007; 435: 421-46.
95. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr Opin Cell Biol 2009; 21(6): 894-9.
96. Blokhina O, Fagerstedt KV. Oxidative metabolism, ROS and NO under oxygen deprivation. Plant Physiol Biochem 2010; 48(5): 359-73.
97. Block ER, Patel JM, Edwards D. Mechanism of hypoxic injury to pulmonary artery endothelial cell plasma membranes. Am J Physiol 1989; 257(2 Pt 1): C223-C231.
98. Grishko V, Solomon M, Breit JF, et al. Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene. FASEB J 2001; 15(7): 1267-9.
99. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 2000; 275(33): 25130-8.
100. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000; 275(35): 26765-71.
101. Kietzmann T, Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 2005; 16(4-5): 474-86.
102. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26(28): 4148-57.
103. MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71(18): 5950-4.
104. Chang CJ, Hsu CC, Chang CH, et al. Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep 2011; 26(4): 1003-10.
105. McCarty MF. Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. Med Hypotheses 2012; 78(2): 262-9.
106. Li Y, VandenBoom TG, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69(16): 6704-12.
107. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009; 8(6): 843-52.
108. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006; 1: e116.
109. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67(23): 11111-6.
110. Dickey JS, Zemp FJ, Martin OA, et al. The role of miRNA in the direct and indirect effects of ionizing radiation. Radiat Environ Biophys 2011; 50(4): 491-9.
111. Saleh AD, Savage JE, Cao L, et al. Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS One 2011; 6(10): e24429.
112. Simone NL, Soule BP, Ly D, et al. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 2009; 4(7): e6377.
113. Wang Z, Liu Y, Han N, et al. Profiles of oxidative stress-related microRNA and mRNA expression in auditory cells. Brain Res 2010; 1346: 14-25.
114. Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008; 12(12): 2171-6.
115. Moriyama T, Ohuchida K, Mizumoto K, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8(5): 1067-74.
116. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70(9): 3606-17.
117. Bao B, Ali S, Banerjee S, et al. Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression. Cancer Res 2012; 72(1): 335-45.
118. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23(18): 2152-65.
119. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302(1): 1-12.
120. Zhang Z, Sun H, Dai H, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009; 8(17): 2756-68.
121. Golestaneh AF, Atashi A, Langroudi L, et al. miRNAs expressed differently in cancer stem cells and cancer cells of human gastric cancer cell line MKN-45. Cell Biochem Funct 2012; 30(5): 411-8.
122. Han M, Wang Y, Liu M, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012; 103(6): 1058-64.
123. Nie Y, Han BM, Liu XB, et al. Identification of MicroRNAs involved in hypoxia-and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci 2011; 7(6): 762-8.
124. Han M, Wang Y, Liu M, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012; 103(6): 1058-64.
125. Mathe E, Nguyen GH, Funamizu N, et al. Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide. Int J Cancer 2012; 131(3): 760-5.
126. Thulasingam S, Massilamany C, Gangaplara A, et al. miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells. Mol Cell Biochem 2011; 352(1-2): 181-8.
127. Bao B, Ahmad A, Kong D, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 2012; 7(8): e43726.
128. Bao B, Ali S, Ahmad A, et al. Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment. PLoS One 2012; 7(12): e50165.
129. Hulsmans M, De KD, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J 2011; 25(8): 2515-27.
130. Zhang X, Ng WL, Wang P, et al. MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFalpha. Cancer Res 2012; 72(18): 4707-13.
131. Guessous F, Zhang Y, Kofman A, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010; 9(6): 1031-6.
132. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7(16): 2591-600.
133. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009; 8(21): 2013-24.
134. Kong D, Heath E, Chen W, et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res 2012; 4(1): 14-23.
135. Roy S, Levi E, Majumdar AP, et al. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol 2012; 5: 58.
136. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009; 8(21): 2013-24.
137. Aranha MM, Santos DM, Sola S, et al. miR-34a regulates mouse neural stem cell differentiation. PLoS One 2011; 6(8): e21396.
138. Guo Y, Li S, Qu J, et al. MiR-34a inhibits lymphatic metastasis potential of mouse hepatoma cells. Mol Cell Biochem 2011; 354(1-2): 275-82.
139. Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008; 582(10): 1564-8.
140. Wang X, Meyers C, Guo M, et al. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int J Cancer 2011; 129(6): 1362-72.
141. Chang SJ, Weng SL, Hsieh JY, et al. MicroRNA-34a modulates genes involved in cellular motility and oxidative phosphorylation in neural precursors derived from human umbilical cord mesenchymal stem cells. BMC Med Genomics 2011; 4: 65.
142. Nalls D, Tang SN, Rodova M, et al. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011; 6(8): e24099.
143. Sun L, Wu Z, Shao Y, et al. MicroRNA-34a Suppresses Cell Proliferation and Induces Apoptosis in U87 Glioma Stem Cells. Technol Cancer Res Treat 2012; 11(5): 483-90.
144. Dutta KK, Zhong Y, Liu YT, et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 2007; 98(12): 1845-52.
145. Pavlides S, Tsirigos A, Migneco G, et al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9(17): 3485-505.
146. Bai XY, Ma Y, Ding R, et al. miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes. J Am Soc Nephrol 2011; 22(7): 1252-61.
147. Babar IA, Slack FJ, Weidhaas JB. miRNA modulation of the cellular stress response. Future Oncol 2008; 4(2): 289-98.
148. Li Y, VandenBoom TG, Wang Z, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70(4): 1486-95.
149. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 2010; 42(6): 363-9.
150. Bhaumik D, Scott GK, Schokrpur S, et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27(42): 5643-7.
151. Liu M, Sakamaki T, Casimiro MC, et al. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 2010; 70(24): 10464-73.
152. Hung PS, Chang KW, Kao SY, et al. Association between the rs2910164 polymorphism in pre-mir-146a and oral carcinoma progression. Oral Oncol 2012; 48(5): 404-8.
153. Chen T, Huang Z, Wang L, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res 2009; 83(1): 131-9.
154. Pogue AI, Percy ME, Cui JG, et al. Up-regulation of NF-kB-sensitive miRNA-125b and miRNA-146a in metal sulfate-stressed human astroglial (HAG) primary cell cultures. J Inorg Biochem 2011; 105(11): 1434-7.
155. Takahashi Y, Satoh M, Minami Y, et al. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 2010; 119(9): 395-405.
156. Wendlandt EB, Graff JW, Gioannini TL, et al. The role of MicroRNAs miR-200b and miR-200c in TLR4 signaling and NF-kappaB activation. Innate Immun 2012; 18(6): 846-55.
157. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307(1): 26-36.
158. Iliopoulos D, Lindahl-Allen M, Polytarchou C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39(5): 761-72.
159. Leal JA, Lleonart ME. MicroRNAs and cancer stem cells: Therapeutic approaches and future perspectives. Cancer Lett 2013; 338(1): 174-83.
160. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138(3): 592-603.
161. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle 2012; 11(6): 1235-46.
162. Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011; 17(12): 1627-35.
163. Magenta A, Cencioni C, Fasanaro P, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2011; 18(10): 1628-39.
164. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2(9): 807-13.
165. Toyama T, Kondo N, Endo Y, et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol 2012; 42(4): 256-63.
166. Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35(6): 856-67.
167. Ivan M, Harris AL, Martelli F, et al. Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med 2008; 12(5A): 1426-31.
168. Vosa U, Vooder T, Kolde R, et al. Meta-analysis of microRNA expression in lung cancer. Int J Cancer 2013; 132(12): 2884-93.
169. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14(5): 1340-8.
170. Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010; 9(6): 1072-83.
171. Devlin C, Greco S, Martelli F, et al. miR-210: More than a silent IUBMB Life 2011; 63(2): 94-100.
172. Favaro E, Ramachandran A, McCormick R, et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010; 5(4): e10345.
173. Gee HE, Camps C, Buffa FM, et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010; 116(9): 2148-58.
174. Hebert C, Norris K, Scheper MA, et al. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007; 6: 5.
175. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 2010; 3(2): 109-13.
176. Kulshreshtha R, Ferracin M, Negrini M, et al. Regulation of microRNA expression: the hypoxic component. Cell Cycle 2007; 6(12): 1426-31.
177. Puissegur MP, Mazure NM, Bertero T, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2011; 18(3): 465-78.
178. Quero L, Dubois L, Lieuwes NG, et al. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol 2011; 101(1): 203-8.
179. Hu S, Huang M, Li Z, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010; 122(11 Suppl): S124-S131.
180. Huang X, Le QT, Giaccia AJ. MiR-210--micromanager of the hypoxia pathway. Trends Mol Med 2010; 16(5): 230-7.
181. Kulshreshtha R, Davuluri RV, Calin GA, et al. A microRNA component of the hypoxic response. Cell Death Differ 2008; 15(4): 667-71.
182. Pocock R. Invited review: decoding the microRNA response to hypoxia. Pflugers Arch 2011; 461(3): 307-15.
183. Crosby ME, Kulshreshtha R, Ivan M, et al. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009; 69(3): 1221-9.
184. Yoshioka Y, Kosaka N, Ochiya T, et al. Micromanaging Iron Homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem 2012; 287(41): 34110-9.
185. Chen Z, Li Y, Zhang H, et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010; 29(30): 4362-8.
186. Garofalo M, Quintavalle C, Romano G, et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012; 12(1): 27-33.
187. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58(5): 1050-7.
188. Dai R, Li J, Liu Y, et al. miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)-and MEK/ERK-mediated cell cycle regulation. Biol Chem 2010; 391(7): 791-801.
189. Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991; 54(6): 1093-100.
190. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342(8881): 1209-10.
191. Hebert JR, Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998; 90(21): 1637-47.
192. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9(6): 553-7.
193. Kuang HB, Miao CL, Guo WX, et al. Dickkopf-1 enhances migration of HEK293 cell by beta-catenin/E-cadherin degradation. Front Biosci 2009; 14: 2212-20.
194. Sarkar FH, Li Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 2009; 35(7): 597-607.
195. Sarkar FH, Li Y, Wang Z, et al. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des 2010; 16(16): 1801-12.
196. Su Y, Simmen FA, Xiao R, et al. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol Genomics 2007; 30(1): 8-16.
197. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates betacatenin signaling in mammary epithelial cells. Carcinogenesis 2009; 30(2): 331-9.
198. Wagner J, Lehmann L. Estrogens modulate the gene expression of Wnt-7a in cultured endometrial adenocarcinoma cells. Mol Nutr Food Res 2006; 50(4-5): 368-72.
199. Wang Z, Desmoulin S, Banerjee S, et al. Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci 2008; 83(7-8): 293-300.
200. Kameoka S, Leavitt P, Chang C, et al. Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett 1999; 146(2): 161-7.
201. Ruiz-Larrea MB, Mohan AR, Paganga G, et al. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 1997; 26(1): 63-70.
202. Sierens J, Hartley JA, Campbell MJ, et al. In vitro isoflavone supplementation reduces hydrogen peroxide-induced DNA damage in sperm. Teratog Carcinog Mutagen 2002; 22(3): 227-34.
203. Wei H, Wei L, Frenkel K, et al. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 1993; 20(1): 1-12.
204. Zhou Y, Lee AS. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J Natl Cancer Inst 1998; 90(5): 381-8.
205. Calveley VL, Jelveh S, Langan A, et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat Res 2010; 173(5): 602-11.
206. Chan WH, Yu JS. Inhibition of UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermal carcinoma A431 cells by genistein. J Cell Biochem 2000; 78(1): 73-84.
207. Liu Z, Lu Y, Rosenstein B, et al. Benzo[a]pyrene enhances the formation of 8-hydroxy-2'-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells. Biochemistry 1998; 37(28): 10307-12.
208. Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112(9): 2296-306.
209. Xia J, Duan Q, Ahmad A, et al. Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cells. Curr Drug Targets 2012; 13(14): 1750-6.